Integration of herbal medicine into modern medical practices: Issues and prospects

Integrative Cancer Therapies

Volumn 1, Issue 3, 2002, Pages 287-293

  Fong, Harry H S ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTICONVULSIVE AGENT; ARISTOLOCHIC ACID; ARTEMISININ; BELLADONNA ALKALOID; CAFFEIC ACID DERIVATIVE; ECHINACEA EXTRACT; ELEUTHEROSIDE B; ELEUTHEROSIDE E; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GINSENOSIDE; GLYCOPROTEIN; HEAVY METAL; HERBACEOUS AGENT; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMMUNOSTIMULATING AGENT; KAVA; MICHELLAMINE B; MONOAMINE OXIDASE INHIBITOR; NON PRESCRIPTION DRUG; OCIMUM BASILICUM EXTRACT; PLANT EXTRACT; POLYACETYLENE; POLYSACCHARIDE; PYRROLIZIDINE ALKALOID; SEROTONIN UPTAKE INHIBITOR; SILYMARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRICULTURE; CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG QUALITY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GOOD MANUFACTURING PRACTICE; HEALTH CARE DELIVERY; HERB; HERB DRUG INTERACTION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; KIDNEY FAILURE; MEDICINAL PLANT; METHODOLOGY; NEOPLASM; NEPHRITIS; NEPHROTOXICITY; ONCOLOGY; PHYTOCHEMISTRY; PHYTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SIDE EFFECT; SKIN TOXICITY; UNITED STATES; URINARY TRACT INFECTION; WORLD HEALTH ORGANIZATION;

EID: 0042322753     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/153473540200100313     Document Type: Review

References (65)

1. World Health Organization. WHO Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. Geneva, Switzerland: WHO; 2001.
2. Bannerman R, Burton J, Chen WC, eds. Traditional Medicine and Health Care Coverage. Geneva, Switzerland: World Health Organization; 1983.
3. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA. 1998;280:1569-1575.
4. Dev S. Ethnotherapeutics and modern drug development: the potential of Ayurveda. Cur Sci. 1997;73:909-928.
5. Dev S. Ancient-modern concordance in Ayurvedic plants: some examples. Environ Health Persp. 1999;107:783-789.
6. Rees L, Weil A. Integrated medicine imbues orthodox medicine in the values of complementary medicine. British Med J. 2001;322:119-120.
7. World Health Organization. Traditional and Modern Medicine - Harmonizing the Two Approaches. Manila, Philippines: WHO, Regional Office for the Western Pacific; 2000.
8. Fitzloff J, Yat P, Lu Z, et al. Perspectives on the quality assurance of ginseng products in North America. In: Huh H, Choi KJ, Kim YC, eds. Advances in Ginseng Research - Proceedings of the 7th International Symposium on Ginseng. Seoul, Korea: The Korean Society of Ginseng; 1998:138-145.
9. Awang DVC, Yat PN, Arnason JT, et al. The American Botanical Council's program of evaluation of "ginseng" products on the North American market. Paper presented at the International Ginseng Conference '99. Ginseng: Its Science and Its Markets. Advances in Biotechnology, Medicinal Applications and Marketing. July 1999; Hong Kong, SAR, China. Abstract No. A17.
10. Monmaney T. Remedy's U.S. Sales zoom, but quality control lags. The Los Angeles Times. August 31, 1998:A1-A10.
11. Constantine GH, Karchesy J. Variations in hypericin concentrations in Hypericum perforatum L. and commercial products. Pharm Biol. 1998;36:365-367.
12. Schulz V, Hubner W-D, Ploch M. Clinical trials with phytopharmacological agents. Phytomedicine. 1997;4:379-387.
13. Reichling J, Saller R. Quality control in the manufacturing of modern herbal remedies. Quart Rev Nat Med. 1998;Spring:21-28.
14. Simon JE. Domestication and production considerations in quality control of botanicals. In: Eskinazi D, Blumenthal M, Farnsworth NR, Riggins CW, eds. Botanical Medicine - Efficacy, Quality Assurance and Regulation. Larchmont, NY: Mary Ann Liebert, Inc Publishers; 1999:133-137.
15. McChesney JD. Quality of botanical preparations: Environmental issues and methodology for detecting environmental contaminants. In: Eskinazi D, Blumenthal M, Farnsworth NR, Riggins CW, eds. Botanical Medicine - Efficacy, Quality Assurance and Regulation. Larchmont, NY: Mary Ann Liebert, Inc Publishers; 1999:127-131.
16. Flaster T. Shipping, handling, receipt, and short-term storage of raw plant materials. In: Eskinazi D, Blumenthal M, Farnsworth NR, Riggins CW, eds. Botanical Medicine - Efficacy, Quality Assurance and Regulation. Larchmont, NY: Mary Ann Liebert, Inc Publishers; 1999:139-142.
17. Busse W. The processing of botanicals. In: Eskinazi D, Blumenthal M, Farnsworth NR, Riggins CW, eds. Botanical Medicine - Efficacy, Quality Assurance and Regulation. Larchmont, NY: Mary Ann Liebert, Inc Publishers; 1999:143-145.
18. Southwell IA, Campbell MH. Hypericin content variation in Hypericum perforatum in Australia. Phytochemistry. 1991;30:475-478.
19. Campbell MH, May CE, Southwell IA, Tomlinson JD, Michael PW. Variation in Hypericum perforatum L (St. John's wort) in New South Wales. Plant Protection Quart. 1997;12:64-66.
20. Bauer R. Echinacea: Biological effects and active principles. In: LD Lawson and R Bauer. eds. Phytomedicines of Europe. Chemistry and Biological Activity. Washington, DC: American Chemical Society; 1988:140-157.
21. Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. In: Wagner H, Farnsworth NR, eds. Economic and Medicinal Plant Research. Vol 5. New York: Academic Press; 1991:253-321.
22. Manske RHF. Sources of alkaloids and their isolation. In: Manske RHF, Holmes HL. eds. The Alkaloids. Vol 1. New York: Academic Press; 1950:1-11.
23. James WO. Alkaloids in the plants. In: Manske RHF, Holmes HL. eds. The Alkaloids. Vol 1. New York: Academic Press; 1950:16-86.
24. Hammouda FM, Ismail SI, Hassan NM, Zaki AK, Kamel A. Evaluation of the silymarin content in Silybum marianum (L.) Gaertn. cultivated under different agricultural conditions. Phytoth Res. 1993;7:90-91.
25. Awang DVC. Quality control and good manufacturing practices: safety and efficacy of commercial herbs. Food and Drug Law J. 1997;52:341-344.
26. Slifman NR, Obermeyer WR, Aloi BK, et al. Contamination of botanical dietary supplements by Digitalis lanata. New Engl J Med. 1998;339:806-811.
27. Farnsworth NR. Relative safety of herbal medicines. HerbalGram. 1993;29:36A-367H.
28. Huang WF, Wen K-C, Hsiao M-L. Adulteration by synthetic therapeutic substances of Traditional Chinese Medicine in Taiwan. J Clin Pharmacol. 1997;37:344-350.
29. Espinosa EO, Mann M-J, Bleadsdell B, et al. Toxic metals in selected traditional Chinese medicinals. J Forensic Sci. 1996;1:453-456.
30. World Health Organization. Regulatory Situation of Herbal Medicines. A Worldwide Review. Geneva, Switzerland: WHO; 1998.
31. Mahady GB, Fong HHS, Farnsworth NR. Botanical Dietary Supplements: Quality, Safety and Efficacy. Lisse, Netherlands: Swets & Zeitlinger; 2001.
32. Working Party on Herbal Medicinal Products (HMPWP). Points to consider on good agricultural and collection practices for starting materials of herbal origin. The European Agency for the Evaluation of Medicinal Products. EMEA/HMPWP/31/99 draft; 29 April 2001.
33. World Health Organization. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. Manila, Philippines: WHO, Regional Office for the Western Pacific; 1993.
34. World Health Organization. Guidelines for the Assessment of Herbal Medicines. WHO Technical Report Series No 863, Geneva, Switzerland: WHO; 1996:178-184.
35. World Health Organization. Quality Control Methods for Medicinal Plant Materials. Geneva, Switzerland: WHO; 1998.
36. Houghton PJ. Establishing identification criteria for botanicals. Drug Info J. 1998;32:461-469.
37. Balz J-P. Agronomic aspects of pharmaceutical plants production on the example of Ginkgo biloba. Phytopharmaka in Forschung und Klinischer Anwendung. Vol 4. Paris: Beaufour-IPSEN, 1998:45-50.
38. Li TSC. Echinacea: Cultivation and medicinal value. Herbology. 1998;8(2):122-129.
39. World Health Organization. Good manufacturing practices: Supplementary guidelines for the manufacture of herbal medicinal products. WHO Technical Report Series No. 863. Geneva, Switzerland: WHO; 1996:109-113.
40. Rotblatt MD. Herbal medicine: a practical guide to safety and quality assurance. West J Med. 1999;171:172-175.
41. Denham A. Using herbs that contain pyrrolizidine alkaloids. European J Herbal Med. 1996;2:27-38.
42. Menges U, Stotzem CD. Toxicity of aristolochic acid - a sub-acute study in male rats. Med Sci Res. 1992;20:223-224.
43. Menges U, Stotzem CD. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxiol. 1993;67:307-311.
44. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387-391.
45. Hashimoto K, Higuchi M, Makino B, et al. Quantitative analysis of aristolochic acids, toxic compounds contained in some medicinal plants. J Ethnopharmacol. 1999;64:185-189.
46. Nortier JL, Muniz Martinez M-C, Schmeiser HH. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New Engl J Med. 2000;342:1686-1692.
47. Chen JK. Nephropathy associated with the use of Aristolochia. HerbalGram. 2000;48:44-45.
48. Ernst E. Second thoughts about safety of St. John's wort. Lancet. 1999;354:2014-2016.
49. Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion. 2000;13:4-15.
50. Pennachio DL. Drug-herb interactions: how vigilant should you be? Patient Care. 2000;19:41-68.
51. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Therap. 1999;66:338-345.
52. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 2000;355:547-548.
53. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;358:547-549.
54. De Maat MMR, Hoetelmans RMW, Mathôt RAA, et al. Drug interaction between St. John's wort and nevirapine. AIDS. 2001;15:420-421.
55. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33:853-855.
56. World Health Organization. WHO Monographs on Selected Medicinal Plants. Vol 1. Geneva, Switzerland: WHO; 1999.
57. World Health Organization. WHO Monographs on Selected Medicinal Plants. Vol 2. Geneva, Switzerland: WHO; 2002.
58. Ernst E, Pittler MH, Stevinson C, White A. The Desktop Guide to Complementary and Alternative Medicine. Baltimore, Md: WB Saunders; 2001.
59. World Health Organization. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. Manila, Philippines: WHO, Regional Office for the Western Pacific; 1993.
60. Anonymous. Medicinal herbs: NTP extracts the facts. Environ Health Perspect. 1999;107:A604-605 (NIEHS News)
61. Vickers A, Cassileth B, Ernst E, et al. How should we research unconventional therapies. Intern J Technol Assess Health Care. 1997;13:111-121.
62. Churchill W. Implications of evidence based medicine for complementary and alternative medicine. J Chinese Med. 1999;(59): 32-35.
63. Nahim R, Straus SE. Research into complementary and alternative medicine: problems and potential. British Med J. 2001;322:161-163.
64. Tyler VE. Product definition deficiencies in clinical studies of herbal medicines. Scientific Rev Altern Med. 2000;4:17-21.
65. World Health Organization. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series, No 850. Geneva, Switzerland: WHO; 1995.